Convincing evidence shows that mesenchymal stem cells (MSCs) possess immunomodulatory properties, which may play a role in the maintenance of peripheral tolerance, the induction of transplantation tolerance and control of autoimmunity. Although there already data supporting their clinical efficacy in controlling some of the problems of hemopoietic stem cell (HSC) transplantation, concerns remain over the potential of systemic immune suppression and tumor progression. In this issue of Leukemia, Ning et al. 1 report the results of their study on the use of MSC for the prevention of graft-versus-host disease (GVHD) in patients with hematological malignancies subjected to allogeneic HSC transplantation. This is the first randomized study addressing benefits and disadvantages of MSC infusions in the context of HSC allografting. A total of 30 patients were enrolled, most of them with acute myeloid leukemia, and randomized to receive HSC from a HLA-identical sibling donor with or without culture-expanded MSC from the same HSC donor, at a dose range of 0.3-15.3 Â 10 5 MSC per kg. They found that only 1 out of 10 patients in the group receiving MSC developed grade II acute GVHD as compared to 8 out of 15 patients in the non-MSC group. Strikingly, the relapse rate of MSC group was significantly higher than that of non-MSC group (60 versus 20%), leading to the conclusion that MSC efficiently prevent GVHD but also negatively affect graft-versus-leukemia (GVL).
Even before testing their clinical efficacy in animal models, 2, 3 the immunosuppressive capacities of MSC were evaluated in the field of clinical allogeneic HSC transplantation to prevent GVHD. In an open-label multicenter clinical trial from Lazarus et al., 4 1.0-5.0 Â 10 6 kg À1 culture-expanded MSC derived from the bone marrow of the original HSC donor were coinfused with HSC in 46 patients. In comparison with historical controls, no difference in prevention of graft rejection and incidence of GVHD was observed. It was not surprising, therefore that the number of relapsing patients was unchanged.
The first experience with the use of MSC for the prevention of GVHD was reported by Lee et al., 5 who suggested that the injection of MSC enhanced engraftment, accelerated immune reconstitution and suppressed GVHD following T-cell-depleted HLA haplotype-mismatched HSC transplantation in a 20-yearold woman with high-risk acute myelogenous leukemia. The first documented observation of the clinical efficacy in GVHD was reported by the Karolinska Transplant Centre, which successfully treated a 9-year-old boy with steroid-resistant grade IV acute GVHD using haploidentical third-party MSC. 6 More recently, the results of a phase I-II study in children undergoing haploidentical HSC transplantation were reported. The co-transplantation of MSC from the same HSC donor was associated with a significant reduction of graft failure rate as compared to historic controls. 7 Although very encouraging, the long-term outcome of both anecdotal and full series is not yet available.
The clinical efficacy is believed to be the consequence of the MSC-mediated immunosuppression but the mechanisms have not yet been elucidated. Regardless of the different experimental approaches and the diverse immune functions analyzed, MSC prevent the proliferation of T cells in response to mitogenic or antigenic stimuli both in humans and mice (reviewed in Dazzi and Horwood 8 ) . MSC also inhibit B 9 and natural killer 10 cell proliferation as well as dendritic cell differentiation and function. 11 Glennie et al. 12 demonstrated that MSC-mediated immunosuppression is produced via an antiproliferative effect, which arrests target cells at early stages of cell cycle. This translates in a profound inhibition of cell proliferation despite partial conservation of effector function. The molecular mechanisms underlying these effects are not yet clarified but are likely to be mediated by direct cell-to-cell interactions and soluble factors. Transforming growth factor-b, indoleamine deoxydase, prostaglandin E2, nitric oxide and most recently insulin-like growth factor-binding proteins have been proposed as candidate molecules (reviewed in Nauta and Fibbe 13 ). The antiproliferative effect of MSC is not confined to immune cells but also affects cells of different tissue origin, including hematopoietic and non-hematopoietic tumor cell lines. Similar to what was observed on T cells, the effect is associated to an accumulation of tumor cells predominantly in G1 phase associated with the downregulation of cyclin D2.
14 Furthermore, it appears that stemness is not a property required to exhibit immunosuppressive/antiproliferative activity, but is a fundamental characteristic of all stroma, as fibroblasts and terminally differentiated mesenchymal cells also inhibit the proliferation and prevent the apoptosis of activated T cells. [15] [16] [17] Therefore, the highly acclaimed MSC-mediated immunosuppression may but be a novel version of the known role of fibroblasts in the modulation of inflammation. 18 The property of regulating stem cell renewal and differentiation as well as the capacity of suppressing cell proliferation can all be ascribed to the central role of stroma in the regulation of tissue generation, maintenance and repair in a specialized anatomic location, the 'niche'. 19 Cell-cycle regulation by the niche is critical for the fate of HSC, as the quiescent state is indispensable for HSC self-renewal and life-span. Stromal cells balance quiescence and cell division in the stem cell niche, thus regulating long-term hematopoiesis. 20 The interplay between the supporting effects of MSC in stem cell growth and differentiation and their immunosuppressive properties has been exploited by some successful clinical experiences in idiopathic aplastic anemia, indicating the functional contribution of transplanted MSC to hematopoietic regeneration. 7, 21 The study published in this issue of Leukemia by Ning et al. is significant in that it shows in a randomized clinical trial that MSC transplantation, although beneficial, comes at a high price, as the prevention of GVHD is associated with a higher incidence of leukemia relapse. For those active in the field of HSC transplantation, these data are like a deja vu, when in the eighties we learnt that prevention of GVHD was associated with loss of GVL. 22 In fact, the donor T cells contained in the HSC preparation do not discriminate between the transplantation antigens, namely the minor histocompatibility antigens, 23 expressed on leukemia and on normal tissues. 24 Therefore, as the T cells affecting GVHD and GVL are the same, it is not
shows increased leukemia relapse rate in patients treated with MSC. Not only is the MSC antiproliferative effect non-specific, but also in this case targeting GVHD has unavoidably led to impairment of GVL.
However, there is still an aspect that does not entirely fit with the data, that is, the absence of differences in the number of infectious events in the group of patients treated with MSC. A non-selective immunosuppression would have equally affected patients' antiviral immunity. Therefore, it is possible that other mechanisms are involved in the clinical consequences of MSC transplantation. Cancer is organized in a manner similar to normal tissue, resourced by sub-population of stem cells dependent on a stromal cell 'niche'. Multiple mechanisms are potentially capable to impair tumor eradication in HSC transplantation. 25 Not only the dynamic interaction between cancer and stromal cells can favor tumor progression, 14, 26, 27 but recent evidence supports the capability of the hematopoietic microenvironment to be the sole causative mechanism of cancer development. 28 Thus, the transplantation of MSC could tip the balance in favor of growth and progression of leukemic cells.
The critical issues that we have outlined require an answer. In particular, distinguishing whether the increased relapse rate in the patients infused with MSC is the result of immunosuppression or the consequence of the 'niche' function is of fundamental importance for the future of MSC-based therapies. The investigation of MSC homing to the tumor may help in clarifying the mechanisms responsible for the clinical outcome. In fact, although there is evidence that MSC can expedite tumor metastasis by mechanisms depending on continuing contact with stromal cells, 26 other models are not consistent with this prerequisite as the analysis of the tumor tissues failed to show the presence of MSC.
14 Accordingly, tumors also grow faster when MSC are injected systemically or subcutaneously at sites distant from the tumor, thus suggesting the primary role of soluble factors. 29 In conclusion, the efficacy of MSC in GVHD is now being confirmed in this randomized study, which unfortunately has also revealed the expected drawback of increased disease relapse. Identifying the mechanisms responsible for the clinical effect is the only possibility to improve the outcome and provide crucial information to design the new trials for the treatment of autoimmune diseases developed from preclinical studies. 30 One simple answer could be to use third-party MHC-mismatched MSC which, being rejected, 31, 32 may still allow to preserve the beneficial control of GVHD without affecting GVL.
